Tecvayli access in Saudi Arabia: the SFDA named-patient pathway

The first BCMA x CD3 bispecific T-cell engager for relapsed or refractory multiple myeloma, reached through the SFDA Personal Importation Program when the local treatment ladder has been exhausted, the local stocking or formulary listing does not meet the patient's need, or the prior BCMA-directed therapy has failed.

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Tecvayli (teclistamab-cqyv) is a humanised IgG4 bispecific antibody from Janssen Biotech (with the BCMA-bispecific platform co-developed with Genmab) that simultaneously binds B-cell maturation antigen on multiple myeloma cells and CD3 on T cells, redirecting host T-cell cytotoxicity against the malignant plasma cell clone. It is the first BCMA x CD3 bispecific T-cell engager approved for myeloma. The US FDA granted accelerated approval on 25 October 2022, converted to traditional approval on 5 March 2026, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli may be locally registered in the Kingdom but constrained by formulary listing, treatment-centre accreditation for BCMA bispecific administration, or out-of-pocket affordability; for those gaps, the SFDA Personal Importation Program is the lawful access route. Reserve Meds coordinates DSCSA-compliant US specialty wholesale procurement under the REMS-equivalent channel, the SFDA documentation kit, and the validated 2 to 8 degrees Celsius cold-chain shipment to the treating haematology-oncology centre.

Reserved for you.

Why patients in Saudi Arabia need Tecvayli via the named-patient pathway

Tecvayli has a broad international registration footprint including European Commission conditional marketing authorisation (granted 24 August 2022, the first worldwide regulatory approval of teclistamab), UK MHRA registration, PMDA Japan approval, and approvals or registrations across Canada, Australia, Switzerland, Israel, Brazil, and a growing set of Gulf, Asian, and Latin American markets through Janssen's affiliates and local agents. In the Kingdom, Tecvayli may be locally registered, but the access gap that brings Saudi patients to the SFDA Personal Importation Program is rarely registration alone. It is registered-but-not-stocked at the specific hospital where the patient is being treated, registered with a narrower indication than the FDA approval, formulary-excluded or cost-prohibitive at the patient's plan tier, or constrained by the treatment centre's accreditation for BCMA bispecific administration with the 48-hour inpatient observation that the prescribing risk evaluation framework requires.

The clinical pull for Tecvayli is strong. BCMA x CD3 bispecific therapy is a key sequencing option for a patient who has progressed on BCMA-directed CAR-T (Carvykti or Abecma) when CAR-T has been internationally referred and produced a remission of limited duration, or for patients ineligible for CAR-T because of disease tempo, organ function, or lack of access to a CAR-T capable centre. The MajesTEC-1 trial established the relapsed and refractory multiple myeloma efficacy profile with an overall response rate of approximately 63 percent in heavily pretreated patients, with very good partial response or better in approximately 58 percent and complete response or better in approximately 39 percent. For Saudi families coordinating care for a relative who has exhausted standard triple-class therapy and either progressed on CAR-T or cannot reach a CAR-T centre, the SFDA Personal Importation Program is the route to US-sourced supply with documented chain of custody for a specific named patient.

The SFDA Personal Importation Program for Tecvayli

The SFDA Personal Importation Program allows a SCFHS-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. Applications are filed through the dispensing institution's import pharmacy and reviewed by SFDA's Drug Sector, with named-patient transactions increasingly routed through the Ghad digital platform.

For a Tecvayli case, the application package contains the clinical justification letter from the treating haematologist (multiple myeloma diagnosis with ICD-10 coding and ISS or R-ISS stage, full prior-line documentation including proteasome inhibitor exposure, immunomodulatory agent exposure, anti-CD38 antibody exposure, and any prior BCMA-directed therapy with documented progression or ineligibility, the requested dosing and step-up plan, and the inpatient observation and monitoring plan), SCFHS license verification, an SFDA-format anonymised patient identifier, product details (Tecvayli 30 mg/3 mL and 153 mg/1.7 mL single-dose vials, Janssen Biotech as US license holder, country of origin, requested quantity, lot, expiry), the destination dispensing facility license, and a chain-of-custody plan covering 2 to 8 degrees Celsius cold-chain handling with continuous temperature monitoring, full DSCSA serialisation on the outbound US leg, and customs documentation that supports refrigerated handling at port of entry.

The clinical-justification angle specific to Tecvayli is institutional capability sign-off. The treating institution must have the infrastructure to manage cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, with inpatient observation capability for 48 hours after each of the three step-up doses and after the first full treatment dose. The treating haematologist's letter typically names the prior triple-class therapy (specific proteasome inhibitor, IMiD, and anti-CD38 agent), any prior BCMA CAR-T (Carvykti or Abecma) and the progression context or CAR-T ineligibility rationale, the planned step-up schedule (Day 1: 0.06 mg/kg subcutaneously, Day 4: 0.3 mg/kg subcutaneously, Day 7: 1.5 mg/kg subcutaneously, then weekly 1.5 mg/kg maintenance with the option to transition to every-two-week dosing after sustained complete response for at least six months), the premedication plan (corticosteroid, antihistamine, and antipyretic 1 to 3 hours before each step-up and the first treatment dose), the CRS and ICANS management plan, and the IgG monitoring and infection surveillance plan.

Approval timelines for routine cases at established tertiary haematology-oncology centres typically run 10 to 21 business days where the institution has prior BCMA bispecific experience; cases at institutions onboarding to bispecific therapy for the first time may extend to six to eight weeks while SFDA reviews the cold-chain plan, the inpatient observation capability, and the prescriber qualification documentation. The SFDA retains discretion on timing and we do not promise specific durations.

Where Tecvayli gets dispensed in Saudi Arabia

Tecvayli requires an institution with multiple myeloma haematology-oncology capability, inpatient observation infrastructure for 48 hours after each step-up dose and after the first full treatment dose, validated 2 to 8 degree Celsius cold-chain storage, CRS and ICANS management protocols including tocilizumab availability, and named-patient import pharmacy infrastructure. The operative institutions in the Kingdom include King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Jeddah, and Madinah, which holds the most established myeloma, transplant, and cellular therapy programme in the Kingdom and has run the relevant Janssen and BMS clinical trials at multiple sites; King Abdulaziz Medical City and the Ministry of National Guard Health Affairs network in Riyadh and Jeddah, with strong haematology service lines and inpatient capability for bispecific step-up; King Saud University Medical City; King Fahad Specialist Hospital Dammam; and the major private networks including Dr. Sulaiman Al Habib Medical Group, Dr. Soliman Fakeeh Hospital, Saudi German Hospital, and Dallah Hospital, where haematology service lines have the inpatient infrastructure for the early-cycle step-up window.

The step-up dosing schedule (Day 1: 0.06 mg/kg, Day 4: 0.3 mg/kg, Day 7: 1.5 mg/kg, then 1.5 mg/kg weekly thereafter, with optional transition to 3 mg/kg every two weeks after sustained complete response for at least six months) is administered subcutaneously. Each of the three step-up doses and the first full treatment dose require 48-hour inpatient observation per Janssen protocol. The dispensing pharmacy releases the doses to the inpatient ward during step-up and to the outpatient infusion or self-administration arm once the patient is on weekly or biweekly maintenance.

For patients outside the major centres, the standard route is an SFDA-licensed specialty importer in Riyadh or Jeddah filing the PIP application and coordinating delivery under chain-of-custody documentation. Where the local hospital does not have the inpatient bispecific step-up capability, the patient travels to a major Riyadh, Jeddah, or Dammam centre for the inpatient step-up window before returning to local outpatient maintenance.

Real cost picture for Tecvayli in Saudi Arabia

US wholesale acquisition cost for Tecvayli is approximately USD 25,000 per month at maintenance dosing for an average-weight adult, per Janssen published pricing. Per-vial pricing on the 153 mg/1.7 mL vial sits at approximately USD 7,800 per vial and the 30 mg/3 mL vial at approximately USD 1,530 per vial. Monthly cost depends on the weekly versus biweekly schedule and the patient's weight. The Saudi riyal is pegged to the US dollar at approximately 3.75 SAR to 1 USD, so a maintenance month at US WAC equivalents converts to approximately SAR 94,000. The step-up window carries lower drug cost because step-up doses are subtherapeutic; cumulative cost concentrates in the maintenance phase.

The all-in delivered-to-Kingdom cost typically includes US drug acquisition, cold-chain international logistics in the SAR 1,500 to 5,600 (USD 400 to 1,500) range per shipment, SFDA regulatory documentation handling, customs clearance, and the Reserve Meds coordination fee. The inpatient step-up monitoring fees at the dispensing Saudi hospital are billed by that hospital and are not part of the Reserve Meds quote. Reserve Meds quotes an indicative range at intake and a firm itemised quote after documentation review.

On the insurer side, Bupa Arabia, Tawuniya, and MedGulf Arabia each handle myeloma bispecific named-patient imports case by case under CCHI plan-structure rules and typically with prior authorisation and significant patient coinsurance. Reserve Meds supplies the documentation that lets the insurer assess; the claim itself sits with you or your hospital. Cash-pay is the default operating posture; reimbursement is sought after delivery where the plan permits.

Typical timeline for Tecvayli in Saudi Arabia

From waitlist submission to first step-up dose, the typical Tecvayli case in Saudi Arabia runs as follows. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to the treating haematologist. The physician or hospital import pharmacy or SFDA-licensed importer files the PIP application, which clears in 10 to 21 business days for routine cases at experienced centres. In parallel, Reserve Meds aligns US-side specialty pharmacy sourcing, validated cold-chain qualification, and the shipment plan. Once SFDA approval is issued, US release and shipment add 5 to 10 business days for cold-chain transit plus customs clearance into the importer's bonded warehouse or directly to the hospital. The step-up admission is scheduled at the dispensing hospital, typically a 7 to 10 day inpatient window for the three step-up doses (Day 1, Day 4, Day 7) and the first treatment dose at Day 14. The full cycle from waitlist to first treatment dose is typically 4 to 8 weeks. Re-supply on the weekly or biweekly cadence is then planned in 8 to 12 week shipment windows.

What your physician needs to provide

The clinical justification letter is the cornerstone of the SFDA PIP package for Tecvayli. On institutional letterhead, signed by a SCFHS-licensed haematologist or medical oncologist, the letter typically documents the multiple myeloma diagnosis with ICD-10 coding and ISS or R-ISS stage, baseline cytogenetics including high-risk features (del(17p), t(4;14), t(14;16), 1q gain or amplification), the prior treatment history with regimen, duration, best response, and reason for discontinuation for each line, any prior BCMA-directed therapy (cilta-cel, ide-cel, or BCMA antibody-drug conjugate) with response and time to progression, the current disease status with M-protein, light-chain, bone marrow plasma cell percentage, and imaging summary, the rationale for BCMA-directed bispecific therapy specifically, the proposed step-up and maintenance schedule, the premedication plan (a corticosteroid, an antihistamine, and an antipyretic 1 to 3 hours before each step-up dose and the first treatment dose), and the monitoring plan covering cytokine release syndrome and neurotoxicity with tocilizumab availability documented at the dispensing facility.

The letter also addresses the infectious disease surveillance specific to BCMA bispecific therapy: hepatitis B screening at baseline with antiviral prophylaxis where indicated, CMV monitoring during therapy, PJP prophylaxis, baseline IgG monitoring with IVIG support when hypogammaglobulinaemia develops (typical for the BCMA bispecific class given the BCMA-on-plasma-cell on-target consequence), and vaccination status verification before starting therapy. The physician confirms their SCFHS license is active for the requested treatment window and that the dispensing facility has the inpatient monitoring capability and the CRS-ICANS management protocols for the step-up window.

Common questions about Tecvayli in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Tecvayli?

Each insurer assesses bispecific named-patient imports case by case under CCHI plan-structure rules with prior authorisation and typically with significant patient coinsurance. Reserve Meds supplies the documentation; the claim itself sits with you or your hospital. Cash-pay is the default operating posture.

How does Tecvayli compare to Talvey or Elrexfio?

Tecvayli (teclistamab) and Elrexfio (elranatamab) are BCMA-directed bispecifics; Talvey (talquetamab) is GPRC5D-directed. Mechanism-of-action diversification matters when a patient has progressed on BCMA-directed therapy. Within the BCMA-bispecific class, Tecvayli and Elrexfio sit close to each other clinically; the choice typically reflects local availability, the haematologist's experience with each product, and patient-specific tolerance considerations. See our dedicated pages on Talvey in Saudi Arabia and Carvykti in Saudi Arabia.

What about cytokine release syndrome and neurotoxicity?

Tecvayli carries a black box warning for life-threatening or fatal CRS and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome. The inpatient 48-hour observation window after each of the three step-up doses and after the first full treatment dose is precisely to capture and manage these events. Tocilizumab availability at the dispensing facility is a prerequisite. Premedication (corticosteroid, antihistamine, antipyretic) reduces but does not eliminate CRS risk.

What about hypogammaglobulinaemia and infection risk?

BCMA-directed bispecific therapy causes near-universal hypogammaglobulinaemia because BCMA is expressed on normal plasma cells in addition to malignant plasma cells. Patients require baseline IgG monitoring, IVIG support when IgG falls below threshold, PJP prophylaxis, hepatitis B screening with antiviral prophylaxis where indicated, and CMV monitoring. Infection is the leading cause of treatment-related mortality in the bispecific class and the dispensing facility's infectious disease support is integral to the care plan.

Can Tecvayli be self-administered at home after step-up?

The maintenance subcutaneous doses can be administered in an outpatient infusion suite or, after several maintenance doses without CRS or neurologic events, at home with appropriate training and a caregiver present. The first treatment dose and the three step-up doses are inpatient per Janssen protocol. The dispensing Saudi hospital determines the transition point on a patient-by-patient basis.

What about the conversion from weekly to biweekly dosing?

The Janssen prescribing information allows transition from 1.5 mg/kg weekly to 3 mg/kg every two weeks after sustained complete response for at least six months. This is a treating-physician decision based on response durability and patient tolerance. Reserve Meds aligns the re-supply shipment cadence to whichever schedule is in use.

Where Reserve Meds fits in Tecvayli cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating haematologist, do not replace SFDA, and do not replace the Saudi dispensing pharmacy. What we do for a Saudi Tecvayli case is orchestrate US-side specialty pharmacy sourcing through a DSCSA-compliant channel, prepare the regulatory documentation kit the treating haematologist needs (with the CRS and ICANS management framework and the hypogammaglobulinaemia and infection surveillance plan surfaced in the patient-facing case summary), coordinate cold-chain international logistics with continuous temperature monitoring, and assign a single named coordinator through the step-up admission, the maintenance shipment cadence, and the continuity-of-supply window. Bispecific antibody coordination is a defining concierge case for Reserve Meds because the step-up monitoring, the maintenance shipment cadence, the IVIG and prophylaxis framework, and the supportive care framework all sit at the intersection of US sourcing, Saudi regulatory documentation, and dispensing-facility logistics. No prior Reserve Meds dispensed-case experience as of this page; standard NPP coordination under our cold-chain biologic and step-up bispecific playbook applies.

Next step

If the haematologist has prescribed Tecvayli and the family is weighing the cross-border named-patient route, the waitlist is the first step. We confirm eligibility within 24 to 48 hours and send the documentation kit to the treating physician.

Add my Saudi Arabia Tecvayli case to the waitlist